Research & Development
European Commission approves Ojemda as first targeted therapy for relapsed paediatric low-grade glioma
22 April 2026 - French biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Wednesday that the European Commission has granted conditional marketing authorisation for Ojemda (...
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
22 April 2026 - Precision medicine diagnostics company Renalytix plc (LSE: RENX) (OTCQB: RNLXY) revealed on Wednesday that it has completed key regulatory and operational milestones to support the sca...
FDA extends review timeline for Sanofi's Sarclisa subcutaneous formulation in multiple myeloma
22 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has extended by up to three months the tar...
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
22 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has approved an expanded indication for Tz...
Inhibrx provides clinical update on ozekibart (INBRX-109) for colorectal cancer treatment
22 April 2026 - Clinical-stage biopharmaceutical company Inhibrx Biosciences Inc (Nasdaq:INBX) on Tuesday reported updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in com...
LENZ Therapeutics advances VIZZ regulatory expansion with UK submission for presbyopia treatment
20 April 2026 - US pharmaceutical company LENZ Therapeutics Inc (Nasdaq:LENZ) announced on Monday that it has submitted a marketing authorisation application (MAA) to the United Kingdom's Medicin...